Scholar Rock develops antibody medicines that target myostatin for spinal muscular atrophy and other rare neuromuscular diseases. SRRK reports earnings on Tue, Nov 10, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | Truist Securities | Target raised | Buy | |
| Sep 21 | JP Morgan | Target raised | Buy | |
| Sep 15 | Evercore ISI Group | Maintained | Buy | |
| Sep 15 | Piper Sandler | Target raised | Buy | |
| Sep 15 | Jefferies | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in SRRK in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRRK is in one of them and how their past SRRK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SRRK in an article yet. Here's the latest on the wider market.
About Scholar Rock Holding
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts. It develops antibody medicines for people with spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Its lead product candidate, apitegromab, blocks myostatin, a protein that limits muscle growth, and is being studied in SMA and facioscapulohumeral muscular dystrophy. The company is also developing a subcutaneous form of apitegromab and is seeking regulatory approval in the United States and Europe.
- Headquarters
- Cambridge, MA